

MAR 05 2008

Application Serial No. 10/533,158

Attorney Docket No. 7388/84325

Page 3

**Amendments to the Claims:**

The following listing of claims replaces any prior listing of claims.

**List of claims:**

1. (*Currently amended*) An isolated nucleic acid comprising ~~one sequence selected from the group consisting of the nucleic acid sequences~~ sequence set forth in SEQ ID NO:1 to SEQ ID NO:174 in the Sequence Listing.

2. (*Cancelled*)

3. (*Currently amended*) An isolated nucleic acid comprising the full complement ~~complementary~~ to the nucleic acid according to claim 1.

4. (*Cancelled*)

5. (*Currently amended*) An isolated nucleic acid probe comprising ~~nucleic acid (a)~~ ~~or nucleic acid (b)~~:

(a) ~~an isolated nucleic acid comprising a partial length or the full length of one sequence selected from the group consisting of the nucleic acid sequences~~ sequence set forth in SEQ ID NO:1 to SEQ ID NO:174 in the Sequence Listing, ~~or a nucleic acid complementary and the full complement of SEQ ID NO:1 thereto;~~

(b) ~~a nucleic acid capable of hybridizing under stringent conditions to a nucleic acid comprising a partial length or the full length of one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:174 in the Sequence Listing, or a nucleic acid complementary thereto.~~

6. (*Cancelled*)

7. (*Cancelled*)

Application Serial No. 10/533,158

Attorney Docket No. 7388/84325

Page 4

8. (Currently amended). A primer containing ~~DNA (a) or DNA (b):~~

(a) ~~a-DNA~~ an isolated nucleic acid comprising one sequence selected from the group consisting of the nucleic acid sequences sequence set forth in SEQ ID NO:175 to and SEQ ID NO:176 NO:176 in the Sequence Listing, the full complement of SEQ ID NO:175, and the full complement of SEQ ID NO:176. ~~or a DNA complementary thereto;~~

(b) ~~a DNA capable of hybridizing under stringent conditions to the DNA comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:175 to SEQ ID NO:176 in the Sequence Listing, or a DNA complementary thereto.~~

9. (Cancelled)

10. (Cancelled)

11. (Currently amended) A method for determining whether a subject with neuroblastoma has stage 4s neuroblastoma, the method comprising detecting the presence or absence of ~~[[a]] the nucleic acid comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:14 in the Sequence Listing from a clinical tissue sample of neuroblastoma, wherein the presence of SEQ ID NO:1 indicates that the subject has stage 4s neuroblastoma.~~

12. (Currently amended) A nucleic acid microarray comprising a solid phase support and ~~a combination of plural nucleic acids each comprising a partial length or the full length nucleic acid comprising a~~ an isolated nucleic acid comprising the nucleic acid sequence set forth in one of SEQ ID NO:1 to SEQ ID NO:174 in the Sequence Listing immobilized on the solid phase support.

13. (Currently amended) A nucleic acid microarray comprising a solid phase support and at least one isolated nucleic acid selected from the group consisting of a

*Application Serial No. 10/533,158**Attorney Docket No. 7388/84325**Page 5*

~~combination of plural nucleic acids each comprising a~~ the nucleic acid sequence set forth in one of SEQ ID NO:175 to and the nucleic acid sequence set forth in SEQ ID NO:176 NO:200, a nucleic acid sequence set forth in one of SEQ ID NO:519 to SEQ ID NO:540 or a nucleic acid sequence set forth in one of SEQ ID NO:785 to SEQ ID NO:798, wherein the at least one isolated nucleic acid is immobilized on the solid phase support.

14. *(Cancelled)*

15. *(Cancelled)*

16. *(Cancelled)*

17. *(New)* A method for determining whether a subject with neuroblastoma has stage 4s neuroblastoma according to claim 11, wherein the presence of the nucleic acid sequence set forth in SEQ ID NO:1 is detected by a diagnostic agent comprising the isolated nucleic acid probe according to claim 5.

18. *(New)* A method for determining whether a subject with neuroblastoma has stage 4s neuroblastoma according to claim 11, wherein the presence of the nucleic acid sequence set forth in SEQ ID NO:1 is detected by a diagnostic kit comprising one pair of the primers according to claim 8.